IDEXX Laboratories, Inc. $IDXX Stock Sold by Montrusco Bolton Investments Inc.

Montrusco Bolton Investments Inc. lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 317,110 shares of the company’s stock after selling 55,678 shares during the period. IDEXX Laboratories makes up 2.7% of Montrusco Bolton Investments Inc.’s holdings, making the stock its 13th largest position. Montrusco Bolton Investments Inc. owned approximately 0.40% of IDEXX Laboratories worth $165,592,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $26,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the second quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its holdings in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares in the last quarter. Arlington Trust Co LLC grew its position in IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new position in IDEXX Laboratories in the fourth quarter worth approximately $46,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.79% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. KeyCorp assumed coverage on IDEXX Laboratories in a report on Monday. They issued a “sector weight” rating on the stock. Barclays decreased their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Citigroup boosted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Stock Down 0.7%

Shares of IDXX traded down $3.63 during mid-day trading on Tuesday, reaching $520.31. The company’s stock had a trading volume of 445,411 shares, compared to its average volume of 568,993. The company has a market cap of $40.99 billion, a price-to-earnings ratio of 36.59, a price-to-earnings-growth ratio of 2.77 and a beta of 1.55. The business has a fifty day moving average of $536.72 and a 200 day moving average of $552.17. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.